Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-12286 in Chronic Angle-closure Glaucoma
NCT02152774Phase 2
Key facts
- Status
- Unknown
- Start
- May 2014
- Primary completion
- Feb 2015
- Countries
- 1
- Sponsor
- New York Glaucoma Research Institute
- Modality
- Small Molecules
- Drugs
- verosudil
- Conditions
- chronic angle-closure glaucoma (CACG)
01
Overview
Phase 2, randomised, double-blind trial of verosudil in chronic angle-closure glaucoma (CACG) (2 arms), sponsored by New York Glaucoma Research Institute. Primary endpoint: Intraocular Pressure Reduction at 6 months. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
0.5% AR-12286
AR-12286 0.5% ophthalmic solution
0.7% AR-12286
AR-12286 0.7% ophthalmic solution
03
Who it enrols
Patients aged 50-85 with chronic angle-closure glaucoma (CACG) with at least 180 degrees of peripheral anterior synechiae and elevated intraocular pressure (>=22 mmHg).
04
Endpoints
Primary
Intraocular Pressure Reduction
Secondary
Early effect on Intraocular Pressure
Long term effect on Intraocular Pressure
Structural blockage of the trabecular meshwork
Beyond the preview
Go deeper on NCT02152774.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152774.